What is the first-line therapy for Clostridioides difficile infection in adults and how should recurrences be managed?

Treatment of Clostridioides difficile Infection

Oral vancomycin 125 mg four times daily for 10 days or fidaxomicin 200 mg twice daily for 10 days is the first-line therapy for any initial CDI episode, regardless of severity, with fidaxomicin preferred when resources permit because it reduces recurrence by approximately 40% compared to vancomycin. 1, 2

Initial Episode Treatment Algorithm

First-Line Options (All Severity Levels)

• Fidaxomicin 200 mg orally twice daily for 10 days is the preferred regimen, achieving clinical cure rates of 88–92% while lowering recurrence to 13–17% versus 24–27% with vancomycin. 1, 2, 3

• Oral vancomycin 125 mg four times daily for 10 days is an equally acceptable alternative when fidaxomicin is cost-prohibitive or unavailable, with cure rates of 81–92%. 1, 2

• The distinction between non-severe and severe disease does not alter the choice of initial antibiotic—both fidaxomicin and vancomycin are appropriate for either severity category. 2

Severity Classification

• Non-severe CDI: white blood cell count ≤15,000 cells/µL and serum creatinine <1.5 mg/dL. 1, 2

• Severe CDI: white blood cell count ≥15,000 cells/µL or serum creatinine ≥1.5 mg/dL. 1, 2

• The standard 125 mg vancomycin dose is appropriate for both non-severe and severe disease; higher doses do not improve outcomes in non-fulminant cases. 2, 4

Metronidazole (Resource-Limited Settings Only)

• Metronidazole 500 mg orally three times daily for 10 days should be used only when vancomycin and fidaxomicin are unavailable, and only for non-severe CDI. 1, 2

• In severe CDI, metronidazole achieves only 76% cure versus 97% with vancomycin—metronidazole is strongly discouraged for severe disease. 2

• Avoid repeated or prolonged metronidazole courses due to cumulative, potentially irreversible neurotoxicity. 1, 2

Fulminant (Life-Threatening) CDI

Recognition Criteria

• Fulminant CDI is a medical emergency identified by hypotension/shock, ileus, or toxic megacolon. 1, 2

Escalated Regimen

• High-dose oral vancomycin 500 mg four times daily (via mouth or nasogastric tube) plus intravenous metronidazole 500 mg every 8 hours. 1, 2

• If ileus is present, add vancomycin 500 mg in 100 mL normal saline per rectum every 4–12 hours as a retention enema to ensure adequate colonic drug concentrations. 1, 2

• Intravenous vancomycin alone is ineffective because it is not excreted into the colon. 2

Surgical Intervention

• Obtain immediate surgical consultation for total abdominal colectomy with ileostomy when perforation occurs, systemic inflammation fails to improve after 2–5 days of optimal antibiotics, or toxic megacolon develops. 2

• Surgery should be performed early—ideally before serum lactate exceeds 5.0 mmol/L. 2

First Recurrence Management

Treatment Selection Based on Initial Therapy

• If the initial episode was treated with metronidazole: give oral vancomycin 125 mg four times daily for 10 days. 2, 4

• If the initial episode was treated with standard vancomycin: fidaxomicin 200 mg twice daily for 10 days is preferred, reducing second recurrence from ~35% (vancomycin) to ~20% (fidaxomicin). 2, 5

Tapered-and-Pulsed Vancomycin Alternative

When fidaxomicin is unavailable after initial vancomycin failure, employ a prolonged tapered-and-pulsed regimen (total 6–11 weeks): 2, 4

• 125 mg four times daily for 10–14 days

• then 125 mg twice daily for 7 days

• then 125 mg once daily for 7 days

• then 125 mg every 2–3 days for 2–8 weeks (pulse phase)

• The pulse phase is essential—intermittent dosing suppresses vegetative C. difficile while permitting restoration of colonic microbiota. 2

• Maintain the 125 mg dose throughout; escalation to 500 mg is reserved exclusively for fulminant disease. 2, 4

Adjunctive Therapy

• Bezlotoxumab 10 mg/kg IV as a single dose during antibiotic therapy reduces recurrence in high-risk patients (age >65 years, immunocompromised, severe initial disease), but use cautiously in congestive heart failure. 2

Second and Subsequent Recurrences

Treatment Hierarchy

1. Fidaxomicin 200 mg twice daily for 10 days (standard or extended-pulsed regimen). 2, 4

2. Tapered-and-pulsed vancomycin (as described for first recurrence). 2, 4

3. Sequential vancomycin-rifaximin: vancomycin 125 mg four times daily for 10 days followed by rifaximin 400 mg three times daily for 20 days. 2, 4

Fecal Microbiota Transplantation (FMT)

• FMT is strongly recommended after at least two recurrences (three total CDI episodes) that have failed appropriate antibiotic therapy. 1, 2

• Clinical resolution is achieved in 81–92% of patients receiving FMT versus 23–40% with antibiotics alone. 2

• FMT should be performed after completion of the standard antibiotic course, using appropriately screened donor stool. 2

Critical Management Principles

Antibiotic Stewardship

• Discontinue the inciting antibiotic immediately—this is the single most important modifiable factor to reduce recurrence and treatment failure. 1, 2

• When concomitant antibiotics are necessary for other infections, fidaxomicin achieves 90% cure versus 79% with vancomycin, and reduces recurrence by 12% (17% vs 29%). 6

Medications to Avoid

• Avoid antiperistaltic agents (loperamide, diphenoxylate) and opioid analgesics in all CDI patients—they worsen outcomes and increase complications. 2

Monitoring and Endpoints

• Assess clinical response daily; improvement typically occurs within 3–5 days of initiating therapy. 2

• Do not perform a "test of cure" after completing therapy—clinical improvement is the appropriate endpoint. 2, 4

Treatment Duration

• A standard 10-day course is appropriate for all initial episodes and most recurrences. 2, 4

• Extend to 14 days only when clinical response is delayed, particularly after escalation from metronidazole to vancomycin. 2, 4

Common Pitfalls to Avoid

• Do not use metronidazole for severe CDI—cure rates are substantially lower (66% vs 79% with vancomycin). 2

• Do not omit rectal vancomycin in fulminant CDI with ileus—oral therapy alone may not reach the colon. 1, 2

• Do not skip the pulse phase of tapered vancomycin—the intermittent dosing during weeks 2–8 is critical for preventing relapse. 2

• Do not delay surgical consultation in fulminant CDI—operative intervention should occur before lactate exceeds 5.0 mmol/L. 2

• Do not use intravenous vancomycin for CDI—it does not achieve therapeutic colonic concentrations. 2

Evidence Strength and Nuances

The 2018 IDSA/SHEA guidelines provide strong recommendations with high-quality evidence for vancomycin and fidaxomicin as first-line therapy, representing a major shift from prior metronidazole-based algorithms. 1 The superiority of fidaxomicin in preventing recurrence is consistent across multiple randomized trials, with the most robust data from the phase 3 OPT-80 studies showing a 40% relative reduction in recurrence. 3, 5, 7 However, fidaxomicin did not demonstrate reduced recurrence for the epidemic NAP1/027 strain, though this finding has limited clinical applicability given the declining prevalence of this ribotype. 2, 3

The tapered-and-pulsed vancomycin regimen carries only weak recommendation with low-quality evidence in the IDSA/SHEA guidelines, reflecting the absence of controlled trials. 2 Despite this limitation, the strategy remains guideline-endorsed because alternative repeat courses have higher recurrence rates (25–35%), and the biological rationale is sound. 2